Nektar Reports Durable Hair Regrowth With REZPEG, Phase III Alopecia Trial Next
Nektar says REZPEG produced durable hair regrowth in alopecia patients, and the data set up a Phase III trial of the candidate in the autoimmune hair-loss indication.
Topic
Nektar Therapeutics
Topic
Nektar Therapeutics
Nektar Reports Early Onset of Improvement with Rezpegaldesleukin in Atopic Dermatitis
Nektar Therapeutics says rezpegaldesleukin produced atopic dermatitis improvements as early as Week 2, accompanied by molecular c…
Nektar Presents Biomarker Data on Atopic Dermatitis Candidate
Nektar Therapeutics has presented biomarker data on its investigational atopic dermatitis drug, offering early pharmacologic insi…
Nektar Brings Early Biomarker Data for Eczema Candidate to EADV 2026
Nektar Therapeutics presented early biomarker data for its investigational eczema drug at EADV 2026, offering a first public sign…
Nektar to Present Three Rezpegaldesleukin Orals at EADV 2026
Nektar Therapeutics will give three oral presentations on rezpegaldesleukin at the EADV Congress 2026, with titles, endpoints and…